Full Press Release Details
ADVISORY, Nov. 08, 2017 (GLOBE NEWSWIRE) --
InflaRX NV (Nasdaq:IFRX), a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO) on November 8, 2017.
In honor of the occasion, Prof. Niels C. Riedemann, CEO & Founder, will ring the Opening Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Thursday, November 9, 2017 – 9:15 a.m. to 9:30 a.m. ET
InflaRX NV Media Contact:
Katja Arnold / Shaun Brown / Dr. Cora Kaiser
Email: inflarx[at]mc-services.eu
Tel: +49-89-210 2280
Nasdaq MarketSite Media Contact:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
For photos from ceremonies and events, please visit our Instagram page:
For livestream of ceremonies and events, please visit our YouTube page:
For news tweets, please visit our Twitter page:
For exciting viral content and ceremony photos, please visit our Tumblr page:
A live stream of the Nasdaq Opening Bell will be available at:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. The company is also developing additional molecules targeting chronic and inflammation-related diseases. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany. The team consists of renowned experts in complement and clinical research. InflaRx has been previously financed by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC, certain investment funds managed by a leading US investment management firm, bm-t Beteiligungsmanagement Thüringen Gmbh, KfW banking group, Staidson Hongkong Investment Co Ltd, and various international family and industrial investment offices.
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com